Stemtech Stock Fundamentals

STEK Stock  USD 0.05  0  2.80%   
Stemtech fundamentals help investors to digest information that contributes to Stemtech's financial success or failures. It also enables traders to predict the movement of Stemtech OTC Stock. The fundamental analysis module provides a way to measure Stemtech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Stemtech otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Stemtech OTC Stock Return On Asset Analysis

Stemtech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Stemtech Return On Asset

    
  -0.75  
Most of Stemtech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Stemtech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Stemtech has a Return On Asset of -0.7542. This is 91.38% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is notably higher than that of the company.

Stemtech Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Stemtech's current stock value. Our valuation model uses many indicators to compare Stemtech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Stemtech competition to find correlations between indicators driving Stemtech's intrinsic value. More Info.
Stemtech is rated fourth in return on asset category among its peers. It is rated second in profit margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Stemtech's earnings, one of the primary drivers of an investment's value.

Stemtech Return On Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Stemtech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Stemtech could also be used in its relative valuation, which is a method of valuing Stemtech by comparing valuation metrics of similar companies.
Stemtech is currently under evaluation in return on asset category among its peers.

Stemtech Fundamentals

About Stemtech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Stemtech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stemtech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stemtech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. Stemtech Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Stemtech OTC Stock

Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.